NASDAQ: DMIIDrugs Made In America Acquisition II Corp Stock
$10.11-0.01 (-0.1%)
Updated Jul 31, 2026
DMII Price
$10.11
Fair Value Price
N/A
Market Cap
$644.01M
52 Week Low
$9.86
52 Week High
$10.20
P/E
N/A
P/B
-36.15x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.02
Operating Cash Flow
N/A
Beta
0
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DMII Overview
Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DMII's potential to beat the market
- DMII doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Shell Company
Industry Rating
F
DMII
RankedUnranked of 35
RankedUnranked of 35
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.85 | C | |
| $10.21 | C | |
| $11.29 | C |
Be the first to know about important DMII news, forecast changes, insider trades & much more!
DMII News
Overview
Due Diligence Score
–
Industry Average (6)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DMII scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DMII's short-term liabilities ($666.29k) exceed its short-term assets ($351.76k)
Short-term Liabilities Financials
DMII's long-term liabilities ($17.50M) exceed its short-term assets ($351.76k)
Long-term Liabilities Financials
DMII's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more DMII due diligence checks available for Premium users.
Valuation
DMII price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
15.13x
Market
16.13x
DMII price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-36.15x
Industry
50.46x
DMII's financial health
Profit margin
Revenue
$0.0
Net Income
$4.3M
Profit Margin
0%
Assets to liabilities
Assets
$509.7M
Liabilities
$18.2M
Debt to equity
-1.02
DMII's short-term liabilities ($666.29k) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DMII's long-term liabilities ($17.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DMII's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DMII's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$102.5k
Investing
$0.0
Financing
$450.0k
DMII vs Shell Company Stocks
Drugs Made In America Acquisition II Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.